Versant Ventures has invested $30m in Switzerland-based Matterhorn Biosciences to launch the company and assist with the development of its T-cell therapy technology for cancer treatment.
Versant Ventures has invested $30m in Switzerland-based Matterhorn Biosciences to launch the company and assist with the development of its T-cell therapy technology for cancer treatment.